Science
Mechanism of Action
It acts as a reversible antagonist of muscle-type nicotinic acetylcholine receptors (mnAChR) at the neuromuscular junction. By binding, it prevents acetylcholine from initiating muscle contraction, thereby relaxing facial muscles and smoothing expression lines, similar to a Botox-like effect.
Research
Clinical Evidence
High confidence5%
Key findings
- 01 Clinical studies demonstrate significant inhibition of muscle-type nAChR, resulting in muscle relaxation and a decrease in the depth of mimic and age-related wrinkles. Pentapeptide fragments exhibited high inhibitory activity (IC50 = 28 μM) in electrophysiological tests.
- 02 In vitro, complete blockage of current through muscle-type nAChR channels was observed at 150 μg/ml, comparable to other 'viper-like' peptides.
Transparency
Dusting Analysis
The Formula
Formulation
Stability
Peptides of this class are generally stable in aqueous solutions at slightly acidic to neutral pH. Acetylation and amidation enhance its metabolic stability against proteases.
Conflicts
- Strong oxidizing agents
- Proteolytic enzymes
- Extreme pH (<3.0 or >8.0)
Safety
Safety Profile
Preclinical evaluations indicate it is a non-depolarizing muscle relaxant with low affinity for neuronal α7 receptors, reducing potential for systemic toxicity. Animal studies showed no oral toxicity up to 160 mg/kg.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A valuable biomimetic peptide for its potent, targeted action in visibly relaxing facial muscles and smoothing expression lines.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources